COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system

[1]  T. Chang,et al.  Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial , 2021, The Lancet Respiratory Medicine.

[2]  P. Lantz,et al.  Association of Social and Demographic Factors With COVID-19 Incidence and Death Rates in the US , 2021, JAMA network open.

[3]  S. Solomon,et al.  Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis , 2020, European heart journal. Cardiovascular pharmacotherapy.

[4]  T. N. Harrison,et al.  Angiotensin‐Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID‐19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System , 2020, Journal of the American Heart Association.

[5]  J. Sim,et al.  COVID-19 and Survival in Maintenance Dialysis , 2020, Kidney Medicine.

[6]  Yue Wu,et al.  Effects of renin‐angiotensin‐aldosterone system inhibitors on disease severity and mortality in patients with COVID‐19: A meta‐analysis , 2020, Journal of medical virology.

[7]  J. Rigdon,et al.  Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during coronavirus disease 2019: beyond confounding. , 2020, Journal of hypertension.

[8]  Y. Yazdanpanah,et al.  Association between renin–angiotensin–aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment , 2020, Journal of hypertension.

[9]  M. Chung,et al.  Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[10]  N. Cunha,et al.  Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis , 2020, IJC Heart & Vasculature.

[11]  Ying Song,et al.  Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China , 2020, Hypertension Research.

[12]  P. Serruys,et al.  Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.

[13]  C. Granger,et al.  Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial , 2020, American Heart Journal.

[14]  M. Chung,et al.  Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[15]  Jian Chen,et al.  Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. , 2020, JAMA cardiology.

[16]  Junni L. Zhang,et al.  Subgroup balancing propensity score , 2017, Statistical methods in medical research.

[17]  J. Routy,et al.  Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.

[18]  J. Handler,et al.  Systemic implementation strategies to improve hypertension: the Kaiser Permanente Southern California experience. , 2014, The Canadian journal of cardiology.

[19]  Brian K. Lee,et al.  Weight Trimming and Propensity Score Weighting , 2011, PloS one.

[20]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.

[21]  D. Diz,et al.  Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.